Page 311«..1020..310311312313..320330..»

Blue Biotechnology Market Outlook by Industry Revenue, Regions and Top Key Players 2022-2030 This Is Ardee – This Is Ardee

Posted: July 27, 2022 at 3:06 am

Key CompaniesCovered in theBlue Biotechnology MarketResearch areAker Biomarine, Cellgen Biologicals Pvt Ltd., Donald Danforth Plant Science Center, Geomarine Biotechnologies, Glycomar, Marinova, Nurture Aqua Technology Pvt., New England Biolabs, Pices, Pml Application Ltd., Sea Run Holdings, Inc., Shell Marine Products, Sanosil Biotech, and Samudra Biopharma Private Limited.and other key market players.

The report covers the analysis and forecast of the blue biotechnology market on global as well as regional level. The study provides historic data of 2016 along with the forecast for the period between 2017 and 2025 based on revenue (US$ Mn).

Download Free Sample of This Strategic Report:https://reportocean.com/industry-verticals/sample-request?report_id=5444

The study provides a detailed view of the blue biotechnology market, by segmenting it based on by product type, by application, by end- user and regional demand. Robust growth of drug discovery in the past several years propels the growth for the blue biotechnologys market. Growing usage of algae along with other bacteria for producing a new drug is another prime factor driving the market demand. Additionally, extensive use of blue biotechnologys in end-user industries such as pharmaceutical, research organization, healthcare, and others boosts the demand of this market.

Regional segmentation includes the current and forecast demand for North America, Europe, Asia Pacific, Middle East and Africa and Latin America. The segmentation also includes by product type, by application and end- user in all regions. These include different business strategies adopted by the leading players and their recent developments.

A comprehensive analysis of the market dynamics that is inclusive of market drivers, restraints, and opportunities is part of the report. Additionally, the report includes potential opportunities in the blue biotechnology market at the global and regional levels. Market dynamics are the factors which impact the market growth, so their analysis helps understand the ongoing trends of the global market. Therefore, the report provides the forecast of the global market for the period from 2017 to 2025, along with offering an inclusive study of the blue biotechnology market.

Request To Download Sample of This Strategic Report:-https://reportocean.com/industry-verticals/sample-request?report_id=5444

The report provides the size of the blue biotechnology market in 2017 and the forecast for the next eight years up to 2025. The size of the global blue biotechnology market is provided in terms of revenue. Market revenue is defined in US$ Mn. The market dynamics prevalent in North America, Europe, Asia Pacific, Middle East and Africa and Latin America has been taken into account in estimating the growth of the global market.

Market estimates for this study have been based on revenue being derived through regional pricing trends. The blue biotechnology market has been analyzed based on expected demand. Bottom-up approach is done to estimate the global revenue of the blue biotechnology market, split into regions. Based on product type, application, and end- user, the individual revenues from all the regions is summed up to achieve the global revenue for blue biotechnology. Companies were considered for the market share analysis, based on their innovation, end- user and revenue generation. In the absence of specific data related to the sales of blue biotechnology several privately held companies, calculated assumptions have been made in view of the companys penetration and regional presence.

The global blue biotechnology market has been segmented into:

Global Blue Biotechnology Market: By Product Type Pharma Biofuels Food Enzymes Biopolymers Others

Global Blue Biotechnology Market: By Application Vaccine development Drug finding Genomics Others

SPECIAL OFFER (Avail an Up-to 30% discount on this report-https://reportocean.com/industry-verticals/sample-request?report_id=5444

Global Blue Biotechnology Market: By End- User Pharmaceutical companies Biotechnology companies Research organization Healthcare centre Others

Global Blue Biotechnology Market: By Geography North Americao U.S.o Canadao Mexico Europeo U.K.o Franceo Germanyo Italyo Rest of Europe Asia Pacifico Indiao Chinao Japano Rest of Asia Pacific Middle East and Africao South Africao Rest of Middle East and Africa Latin Americao Brazilo Rest of Latin America

Table of Content:

Key Questions Answered in the Market Report

Request full Report:https://reportocean.com/industry-verticals/sample-request?report_id=5444

About Report Ocean:We are the best market research reports provider in the industry. Report Ocean believes in providing quality reports to clients to meet the top line and bottom line goals which will boost your market share in todays competitive environment. Report Ocean is a one-stop solution for individuals, organizations, and industries that are looking for innovative market research reports.

Get in Touch with Us:Report Ocean:Email:sales@reportocean.comAddress: 500 N Michigan Ave, Suite 600, Chicago, Illinois 60611 UNITED STATESTel:+1 888 212 3539 (US TOLL FREE)Website:https://www.reportocean.com

Link:
Blue Biotechnology Market Outlook by Industry Revenue, Regions and Top Key Players 2022-2030 This Is Ardee - This Is Ardee

Posted in Biotechnology | Comments Off on Blue Biotechnology Market Outlook by Industry Revenue, Regions and Top Key Players 2022-2030 This Is Ardee – This Is Ardee

STRM.BIO Receives $2.1 Million SBIR Grant to Advance Extracellular Vesicle Technology for Non-Viral, In Vivo Delivery of Gene Therapies – PR Newswire

Posted: July 27, 2022 at 3:06 am

BOSTON, July 26, 2022 /PRNewswire/ --STRM.BIO, a pre-clinical, VC-backed biotechnology company that is leveraging extracellular vesicles (EVs) to deliver gene therapies and developing new therapeutics for rare blood diseases, announced today it has been awarded a Small Business Innovation Research (SBIR) grant for approximately $2,100,000 from the National Center for Advancing Translational Sciences (NCATS) at the National Institutes of Health (NIH). The award will allow the company to further advance its proprietary EV technology for use as a novel non-viral gene therapy delivery platform.

The specific objective of this NIH funding opportunity is to support the development and evaluation of innovative approaches to deliver genome editing machinery into somatic cells, with the goal of enabling the use of genome editing therapeutics to treat human disease. STRM.BIO has developed a proprietary, large capacity EV-based system for in vivo nucleic acid and protein delivery that specifically targets hematopoietic stem cells (HSCs) in bone marrow, is amenable to large scale commercial manufacture, and presents with low immunogenicity which confers unique potential for repeat dosing.

"It is critical to the future of the field that the next generation of gene therapies be delivered as simple injections in standard clinical settings," said Jonathan Thon, CEO and Founder of STRM.BIO. "Current ex vivo approaches, in which a patient's cells are edited in culture and then transplanted, are not a sustainable model. Patients undergo harsh conditioning before receiving an ex vivo gene therapy treatment, which often has severe side effects and can be fatal. These treatments also require specialized facilities and training and are too expensive to be supported by payers as a routine option. Our EV-based delivery system has the potential to efficiently deliver gene editors safely to the bone marrow following intravenous injectionspecifically the long-term HSCs in the bone marrow we all strive to target for durable gene correction. This is big. This precision targeting creates promising new options to treat rare blood diseases and represents a paradigm shift over HSC transplant."

This SBIR award will enable the company to optimize procedures for loading their proprietary EVs with cargo, further characterize the biodistribution and delivery pattern of cargo-loaded EVs, and verify feasibility of STRM.BIO EVs for in vivo cargo delivery in a pre-clinical model of human genetic hematologic disease. With this grant, the company aims to expand pre-clinical proof-of-concept support for the use of this novel system as a non-viral, in vivo genome editor delivery system for the treatment of inherited hematologic diseases.

About STRM.BIO

Based in Boston, MA, STRM.BIO is a pre-clinical, VC-backed biotechnology company that is leveraging extracellular vesicles (EVs) to deliver gene therapy in a better way: simpler, safer, practical. Our work will open the door to the future of medicine for patients living with rare diseases worldwide. STRM.BIO is committed to bringing gene therapy to life. Please visit strm.bioand follow us on Twitter @STRMbio and on LinkedInto meet our growing team of partners and collaborators and stay up to date on our progress.

SOURCE STRM.BIO

Read more:
STRM.BIO Receives $2.1 Million SBIR Grant to Advance Extracellular Vesicle Technology for Non-Viral, In Vivo Delivery of Gene Therapies - PR Newswire

Posted in Biotechnology | Comments Off on STRM.BIO Receives $2.1 Million SBIR Grant to Advance Extracellular Vesicle Technology for Non-Viral, In Vivo Delivery of Gene Therapies – PR Newswire

What Kathleen Stock gets wrong about the Tories, trans and feminism – CapX

Posted: July 27, 2022 at 3:05 am

Earlier this week the philosopher Kathleen Stock waded into the national press to talk about Tories and our troubled relationship with transgender issues, using Penny Mordaunts tilt for the top job as commentary fuel.

For Stock, the Tories flapping around on gender issues demonstrates a special kind of indifference to half the population, which she ascribes to a hidden ideological commitment to individualism. She also suggests that the many Tory MPs who do oppose self-ID are motivated by opportunism and cultural warmongering, rather than concern about women.

As with everything Stock writes, the article is good, and I urge you to read it, as I urged people to read her book Material Girls when I reviewed it. However, in crucial respects, Stock doesnt understand her opponents. Thats not a knock on her. Id probably make a terrible mess of writing about Labours internal workings. After all, Im a member of the Tory Party.

The most important thing to remember is that the Conservative Party is (famously) a broad church. Whether were broader than Labours similarly broad church, I do not know.

In any case, it is unquestionably true there has long been a spergy transhumanist element in big-C conservatism. People who are keen on open borders, eating bugs, free trade, GMOs, nuclear power, lab-grown meat, pro-fertiliser, effective altruism and so on. Call it the Tom Harwood faction of Toryism, if you like.

Im old enough to remember when The Economist used to run articles calling for the legalisation of drugs in sport. The Adam Smith Institute (ASI) is full of this sort of thing.

Not everything these people say is nonsense. If it were, I would not have consented to one of my novels being launched at the ASI. Theyre often acute on economic matters, sounding early alarms on how quantitative easing would eventually lead to runaway inflation, for example. Theyre also almost certainly right about addressing climate change by dint of nuclear energy, while their pro-fertiliser criticisms of organic agriculture have been emphatically vindicated by recent events in Sri Lanka.

Some of Penny Mordaunts views are of a piece with this tradition. She also shows how one can combine elements of it including things considered woke with patriotism. (Mordaunts patriotism is genuine, by the way. Its not possible to feign that sort of thing and sign up for the Navy reserves.)

My problem with Mordaunts candidacy was her reverse-ferreting on gender issues (which Stock documents superbly), coupled with wider support for pseudoscience: shes a fan of homeopathy on the NHS, for instance. Had she come out and admitted shed changed her views, Id have been much more sympathetic. After all, in 2012, I wrote the following (for my then professional association, the Law Society of Scotland) on aspects of transgenderism. Note: I dont expect an apology from Mordaunt, just as I dont apologise for present Helen disagreeing with past Helen.

When the facts change, I change my mind. What do you do, Sir?

The broader issue is why most of the parliamentary party, the membership, and rusted on Tory voters are opposed to self-ID while simultaneously disclaiming feminism.

In part, its because the ASI types are a minority of both MPs and the membership, and close to non-existent among ordinary voters. Genuine wokies in the electorate will almost always opt for Labour: why go for Woke Lite when you can have the real thing?

Contrary to Stocks argument, it is emphatically not because Tories are indifferent to women or planned to use trans as an issue with which we can wedge Labour (although well take the latter as a present). It is because most Tories think both gender self-identification and feminism are nonsense.

Whod be a feminist?

This isnt just a Tory preoccupation. When the Fawcett Society got a famously honest and scrupulous polling outfit (Survation) to make inquiries of a decent and representative sample, only 7% of Britons self-identified as feminist. Huge, thumping majorities believed in male and female equality, of course, which is often taken to be the definition of feminism. Clearly, however, the public does not see it that way. Perhaps significantly, of those people who called themselves feminist, 68% were more likely to think gender can be a range of identities.

Survation did not disaggregate based on political affiliation, which in itself is revealing. If even 7% of Tories self-identify as feminist, I will eat my Akubra.

One of the great ironies of our time is that feminism has adopted the Victorian Cult of Womanhood: men are uncivilised brutes who women must morally tame. It is an unspoken assumption that the movement of women into, well, everything, is an unalloyed good.

Women are female homo sapiens. The notion that women have no statistically significant, systemic character flaws is nonsense.

Two of the biggest problems when it comes to forming decent, functional, social orders are male violence and male sexual incontinence. The victims, and even more the perpetrators of violence, are overwhelmingly male. A Swedish study found that 1% of adults generated 63% of all violent offences. But that 1% was itself almost 90% male. Males also overwhelmingly dominate sexual offenders, with a similar skewed pattern. Violent crime is a sex-based power-law on steroids.

Thanks to the movement of women into the professions, into creation of culture (women have always been important in its transmission), into management, politics, and media, we are now confronted with a new problem for sustaining functional social orders. Female emotional incontinence, what one old Tory friend calls the blubbering woman problem.

Women are systematically more hostile to freedom of speech than are men. As institutions, including universities, have become more feminised, they have become more hostile to freedom of expression and thought.

Many older Tory men are also angry that they were forced to give up male-only venues historically (they dont use the word spaces) to admit women, and think feminists are hypocrites on this point. Some of these men are not simple-minded golf club bores, either. They see trans as an opportunity to break feminism into what they consider richly deserved pieces.

One reason gender-critical feminists have struggled to win what should be an easy argument is because they havent been able to mount a freedom of association case. And the reason they havent been able to mount a freedom of association claim (which would resonate with older Tories) is because feminism did more to wreck freedom of association in Britain than any other ideology.

Homo sapiens are much more cognitively dimorphic than many people realise. 70% of men have a pattern of personality traits that no woman has; 70% of women have a pattern of personality traits that no man has.

For obvious evolutionary reasons (the elevated risks of pregnancy and childcare and the need to invest in emotionally intense relationships to sustain child-rearing) women are systematically more neurotic, more agreeable and more concerned with propriety (moralised status) than men are. Women are inclined to form cliques (emotionally-intense connections), to engage in relational aggression (attack reputations), and to hide from themselves and others that they are engaging in aggression by claiming it is moral concern.

No, this is not as serious or nasty as sexual assault or violent assault more widely. That reality is something men must simply own. It is why the male prison estate is nine times the size of the female prison estate.

That clear difference in personality traits is also why sex non-conforming behaviour in children is so easy to spot. My father knew I was homosexual when I was five, long before I knew. I never played with the dolls mum and dad bought for me (I have never seen such indifference) and constantly nicked my brothers toys. By the time teenager me was building a scale model of the Colosseum with Meccano, the jury was well and truly in.

Of course, these days, a kid like me would be at risk of transing the gay away.

Feminism has spent decades pretending men and women are interchangeable widgets, and that evolution only had an influence on human development from the neck down. When it has veered away from this claim, its indulged in biological essentialism (viz, women are always kinder) almost as pseudoscientific as Mordaunts apparent enthusiasm for homeopathy. Weirdly, this essentialism doesnt draw on actual evidence of sex-based cognitive dimorphism. Then there are homosexuals. There may not be many of us, but on this sort of thing, we stand out like sore thumbs.

This not individualism or the search for a wedge issue is why the Tory Partys relationship with both trans and feminism is like a Facebook status: its complicated.

Click here to subscribe to our daily briefing the best pieces from CapX and across the web.

CapX depends on the generosity of its readers. If you value what we do, please consider making a donation.

Helen Dale read Law at Oxford and won the Miles Franklin Award for her first novel, 'The Hand that Signed the Paper'. Her latest novel is 'Kingdom of the Wicked'; it was shortlisted for the Prometheus Prize for science fiction.

Columns are the author's own opinion and do not necessarily reflect the views of CapX.

Sign up to our popular email briefing to get the most interesting stories from CapX and the wider web delivered direct to your inbox.

Continued here:
What Kathleen Stock gets wrong about the Tories, trans and feminism - CapX

Posted in Transhumanist | Comments Off on What Kathleen Stock gets wrong about the Tories, trans and feminism – CapX

Tyranny by Numbers | John Waters – First Things

Posted: July 27, 2022 at 3:05 am

The Psychology of Totalitarianismby mattias desmettranslated into english by els vanbrabantchelsea green publishing, 256 pages, $53.25

In 2018, a Polish academic study calledTotalitarianism in the Postmodern Age anticipated a shift in attitudes toward freedom among young Europeans. The research canvassed young people from seven E.U. countries: Austria, the Czech Republic, Germany, Hungary, Poland, Romania, and Slovakia. Almost half of those surveyed did not preclude the right of governments to suspend key democratic political freedoms, while one-third were sanguine about governments engaging in political manipulation, or even lying. A similar proportion could identify values for which they would readily forgo both freedom and democracy. Slightly more than half indicated their support for democracy, while one-third said they had no clearly formulated views. Just half of those surveyed indicated that they might resist incursions upon their freedom, while one in five appeared to regard freedom as inessential.

Two years later, Mattias Desmet, a professor of clinical psychology at Ghent University in Belgium, began to ponder developments in a similar light as he observed the COVID lockdowns rolling out all across the world. His reading of the writings of Gustave Le Bon on the psychology of crowds, and those of Hannah Arendt on twentieth-century totalitarianism, as well as his expertise in statistics, led him to take a deeper interest in what was emerging, and rapidly he came to the conclusion that the overwhelming majority of the world had fallen under a kind of spell.In late 2019, visited by some premonition of impending menace, he went to his bank and paid back his mortgagebecause he felt that society was moving towards a tipping point.

In his new book,The Psychology of Totalitarianism, he elaborates on these instincts in light of what he witnessed during COVID, including the strange phenomenon of peoples apparent indifference to their own deprivations, hurts, and incurred damage from the lockdowns: loss of freedoms, work, income, education, human contact, leisure,etc. The discourse surrounding the coronavirus crisis shows characteristics that are typical of the type of discourse that led to the emergence of the totalitarian regimes of the twentieth century, he writes. The excessive use of numbers and statistics that show a radical contempt for the facts, the blurring of the line between fact and fiction, and a fanatical ideological belief that justifies deception and manipulation and ultimately transgresses all ethical boundaries.

His book offers a description of modern society in the drifts of a mechanistic culture. Totalitarianism is the ineluctable destination. Gummed up in a congealing ideology, man is reduced to a biological organism and subjected to the positivist logic whereby every aspect of thought must be eminently demonstrable. The human person becomes an atomized subject whose entire existence is as though reduced to elementary particles that interact according to the laws of mechanics. This provides the building block of the modern totalitarian statea world, as Osip Mandelstam once observed, rendered fromman, notfor.

In such a culture, the goal is for society to be led by expert technocrats who make decisions based on objective, numerical data. With the coronavirus crisis, Desmet write, this utopian goal seemed very close at hand. For this reason, the coronavirus crisis is a case study par excellence in subjecting the trust in measurements and numbers to critical analysis. Before, societies were governed on the basis of stories; now, we have tyranny by numbers.

He cites Hannah Arendts assertion that totalitarianism is ultimately the belief in an artificially created paradise: Science [has become] an idol that will magically cure the evils of existence and transform the nature of man. The destination of this process is transhumanist manthe merging of the human being with the machine, and the supplanting of the human soul with micro-chips in which all communication will be positivistically constructed.

The key instrument in the creation of a totalitarian state is mass formationin effect, mass hypnosisimposed by propaganda and intimidation. On the one hand, the population is systematically exposed to the relentless voice of the totalitarian leaders; on the other, every alternative voice is systematically eliminated. Fear is the grease of this process. When fearful, the population wants a more controlled society.

The essence of mass formation involves proposing a tangible basis for otherwise unexplainablefree-floatinganxieties, frustrations, and aggression.The appropriate conditions, he says, existed in Western societies long before the COVID crisis.There was an epidemic of burnoutsomething between 40 and 70 percent of people in modern societies experience their jobs as senseless. He points also to the escalating use of psycho-pharmaceutical medicines to treat anxiety and depression.By offering a strategy to deal with the specific anxieties imposed by the coronavirus crisis, the would-be controllers were able to create a bogus solidarity in a society that has destroyed true solidarity. Under these conditions A society saturated with individualism and rationalism suddenly tilts towards the radically opposite condition, towards radically irrational collectivism.

When, writes Desmet, a suggestive story is spread through the mass media that indicates an object of anxietyfor example, the aristocracy under Stalinism, the Jews under Nazism, the virus, and, later the anti-vaxxers, during the coronavirus crisisand at the same time offers a strategy to deal with that object of anxiety, there is a real chance that all the free-flowing anxiety will attach itself to that object and there will be broad social support for the implementation of the strategy to control that object of anxiety.

The hypnotized members of a mass formation close out everything but that which the hypnotist tells them is important. They become not just indifferent to the losses of others, but insensitive to losses of their ownwilling, in fact, to sacrifice everything.

Desmet is at pains to underline that, in a mass formation, the leaders and the led operate in symbiotic manner:The process is as much a pandering to the mob as a manipulation of it, and the hypnotist/leader can himself fall under the spell of his own trance.

In situations of mass formation, saysDesmet, three distinct groups manifest themselves. Only 30 percent, he says, are hypnotized beyond reach. Another 40 percent will from the outset go along with that 30 percent of total believers. Another cohort of about 30 percent, who are not hypnotized, will try to speak out and resist. This group, he says, is extremely heterogeneous and disunited. If they could unite, he says, they could bring the whole thing quickly to an end, but this seldom proves possible.

The slightly better news is that mass formation totalitarianism inevitably self-destructs in time, though by then the cost may be enormous. This is because the leaders need continuously to invent new sources of anxiety and introduce new measures to attack these. At the moment of total control, the leaders mania enters its most fanatical stage, pursuing enemies perceived and imaginedas with Stalins purges of the 1930s. This can only lead to absolute destruction, and yet in the short run is essential to the maintenance of the fear that sustains the mass formation.

Professor Desmet writes that a mass formation can only be combatted by an insistence by those who are immune to it upon telling the truth at all costs. The continued presence of alternative voices serves to curb the viciousness of the rulers and constrains the mob in its excesses. In spite of the growing menace of the times, we have to continue to share rational counter-arguments, in the hope of breaking the link of free-floating anxiety.

He stresses also the importance of the maintenance of ethical principles as an antidote to totalitarianism. The books proffered solution is preventative as opposed to curative. Desmet pursues a fascinating refection on a waterwheel designed by MIT professor Willem Malkus in 1972 to illustrate the work of Edward Lorenz, a mathematician and meteorologist and one of the founders of chaos theory.The device consists of a rotating wheel to which small buckets with a bottom hole are attached. At the top, there is a tap releasing water into the top bucket. At a very low influx, the wheel does not move, because the water flows out of the hole in the bottom of the bucket faster than it flows in. At a slightly higher influx, the bucket fills up and the wheel starts to move, sometimes in one direction, sometimes the other. Once the wheel has chosen a certain direction, its behavior becomes regular and predictable: The greater the influx, the faster it turns.

We cannot predict the specific behaviors of the waterwheel (at least not in its chaotic phase), Desmet outlines, but we can learn the principles by which it behaves. . . . Hence, there is no rational predictability, but there is a certain degree of intuitive predictability. Therefore, Desmet writes, the antidote to totalitarianism lies in an attitude to life that is not blinded by a rational understanding of superficial manifestations of life and that seeks to be connected with the principles and figures that are hidden beneath those manifestations.

And as Desmet rightly points out, this also applies at the societal level: A society primarily has to stay connected with a number of principles and fundamental rights, such as the right to freedom of speech, the right to self-determination, and the right to freedom of religion or belief. These quantities are not expendable adornments, nor cosseting luxuries, nor optional extras. If it loses its intuition of the absolute necessity for these principled fundamentals, a society will lose the sense and memory of how its own equilibrium has been arrived at, and thereafter descend into chaos.

John Watersis an Irish writer and commentator, the author of ten books, and a playwright.

First Thingsdepends on its subscribers and supporters. Join the conversation and make a contribution today.

Clickhereto make a donation.

Clickhereto subscribe toFirst Things.

Photo by Jonathan McIntosh via Creative Commons. Image cropped.

Visit link:
Tyranny by Numbers | John Waters - First Things

Posted in Transhumanist | Comments Off on Tyranny by Numbers | John Waters – First Things

There Is No Such Thing As A Lightning Wallet – Bitcoin Magazine

Posted: July 27, 2022 at 3:05 am

This is an opinion editorial by Roy Sheinfeld, cofounder and CEO of Breez.

Although Breez often ranks highly on lists of the best Lightning wallets, attentive readers will have noticed that we never refer to Breez as a wallet. Were not trying to confuse anyone. On the contrary, its the language of wallets in the context of Bitcoin and Lightning thats confusing.

Wouldnt it be odd to hear someone refer to a fiat payment app, like CashApp, PayPal, or Venmo as a wallet? Nobody, not even the companies themselves, describes them as wallets. And though many Bitcoin and Lightning companies and apps are both more versatile and further removed from what we normally think of as wallets, thats still what we call them.

This is a very common misconstrual, as Gigi has also noted and (independently) debunked. So lets think about what a wallet really is, what a Bitcoin wallet really is, what a Lightning wallet really is, and what we should call these things instead of wallets. We will spare no effort in pursuit of truth and liberating ourselves from scare quotes.

A wallet is a flat case or pouch often used to carry small personal items such as paper currency, credit cards; identification documents such as driver's license, identification card, club card; photographs, transit pass, business cards and other paper or laminated cards. As Giacomo Zucco put it in a recent chat we had, wallets contain little documents and pieces of information we use to interact with others.

What we call wallets first showed up around the 17th century, concurrent with the rise of paper money. And since there are only so many ways to make a small folding case to carry money, wallets havent changed much over the centuries. Compare these two specimens:

On the left is a leather wallet that archaeologists found in the wreckage of a 160-year-old submarine, and on the right is a typical wallet anyone might have in their pocket today.

The big difference isnt in the wallets, but in their contents. The modern wallet contains credit cards, which arose in the middle of the last century. Its no coincidence that credit cards entered the market around the same time as machine-readable standards enabled a transformation from physical to electronic money.

The more we rely on electronic money of whatever kind, the less we rely on wallets. The quantity of electronic money out there now outstrips physical money by a ratio of about 20:1 and each card in the modern wallet can contain balances dozens of times greater than the antique wallet could hold.

Now consider: if you took the modern wallet back 160 years to the time of the antique wallet, people back then could almost certainly tell you what it is and what its used for. Explaining credit and debit cards would be challenging, but they are still physical objects to represent electronic money. The next step would be to explain fiat payment apps, like PayPal. Your great-great-great-grandparents would positively no longer see a wallet there. By the time you try to explain your favorite Bitcoin/Lightning wallet, theyd not even be sure youre speaking the same language.

We in the 21st century might want to expand the definition. Language evolves. Like Giacomo said, wallets contain documents and little pieces of information that let us interact with others. Phones can now contain digital driving licenses (for as long as driving licenses are still a thing), credit card information, photos of loved ones, passwords, contact info and membership info phones can contain the digital versions of everything we carry in leather wallets.

As a matter of fact, the term wallet might cover more of the functions these devices perform than phone. (While were on the topic of proper labeling, phone is such an outdated term! Here in Israel, nobody younger than Methuselah refers to their mobile device as a phone. Get with it anglophones.) So the 21st century correlate of the leather wallet is the phone, right?

But then does it still make sense to call a specific, single-purpose app a wallet? Many apps store information that is readily available to us. If we dont refer to a contacts app on the device as a wallet, even though it replaces traditional business cards, why use that term for a Bitcoin app like BlueWallet or Wallet of Satoshi? Its the phone itself that is the wallet, not the apps. Apps are more like the compartments in the wallet. If were going to adapt the term wallet to our transhumanist age, lets do it right.

Wallets havent changed, but money has, how we store information has, and the term wallet no longer fits.

Bitcoin wallets and physical wallets are both storage media. Physical wallets store bills and cards that are marked with patterns of information. The right tokens with the right patterns denote value, and wallets move those tokens around in meatspace.

Bitcoin wallets also store patterns of information, but they dont directly store value. Bitcoins value is stored only as records on the public blockchain. Bitcoin wallets store private keys that allow users to authorize changes to the blockchain on their behalf. Anything that can store a long string of numbers (i.e., private keys) a piece of paper, neurons, or a fancy, password-protected flash drive would count as a bitcoin wallet. In Bitcoin, the right private keys with the right patterns indirectly denote value, because these keys allow you to move value around in cyberspace.

When friends split a tab with cash, and bills move from one wallet to another, the value is transported. When friends split a tab with bitcoin, the sender encrypts a transaction with the recipients public key and then their numbers shift around on the blockchain, where the value was and remains.

Lets compare again these two kinds of transactions visually:

Again, its easy to see where a wallet fits into the transaction on the left: cash exits wallet A, changes hands, enters wallet B. But when it comes to Bitcoin, what we call wallets are those colored boxes at the bottom containing the private keys. Does does anyone else find that metaphor silly? Like, if a piece of paper, neurons and a flash drive can all be called wallets, even though none of them contain any physical tokens of value or even any bitcoin (whatever that would mean), then isnt that metaphor misleading and unhelpful?

As Kiara Bickers puts it in her great book, Bitcoin Clarity,

With a physical wallet, you are directly holding cash that has value, but with a digital wallet you never hold the value directly, you only ever hold access to it on the blockchain. If you cross a national border from one country into another, did your bitcoin move with you? Well, no. The private keys stored in your bitcoin wallet represent only the ability to move funds, not the funds themselves. (p. 18)

If you want a better term that is less misleading and more accurately descriptive, how about signers? Same denotation plus vastly improved connotations equals Pareto-efficient semantics.

(Hat Tip to NVK and Conor Okus for helping me to think through this question and terminology.)

The term wallet is applied to all manner of Lightning apps. While that term misses the mark in every case, it errs in different directions depending on the type of app in question. Interestingly, reflecting on how Lightning apps are not like wallets does help to identify what they are like, so lets do that.

Custodial wallets dont transport tokens of value, but they do have an analog in the fiat world: bank accounts. Remember how custodial accounts actually work:

In effect, whoevers operating the custodial wallet is an establishment for the custody [and] exchange of money and for facilitating the transmission of funds. In other words, theyre a bank, and thats not my judgment, its the Merriam-Webster Dictionary. Thats just what the word means. And the wallet they provide is an arrangement in which a bank keeps your money but makes it available to you when you want it i.e., a bank account (Cambridge American Dictionary).

Custodial wallets are merely user interfaces for these accounts. They just provide a way for users to pass instructions to and receive messages from the custodial intermediary. Not really wallets, are they?

What a custodial wallet would look like in real life. Doesnt look anything like a wallet, does it? (Image: Adam Norman)

So an actual wallet contains tokens of value to carry them around physical space. A bitcoin wallet (or a signer, remember?), holds your keys, signs transactions and broadcasts them to the network. Custodial Lightning wallets are really like bank accounts, where the value is entrusted to a third-party who transacts on the users behalf.

So what about noncustodial Lightning wallets? (Ugh. It feels awkward just typing that.)

The Lightning Network consists of nodes connected by payment channels. Signing plays a role here too, because every Lightning transaction is a Bitcoin transaction. However, Lightning transactions require routing bitcoin from one Lightning node to another and another and another, along their payment channels, until the payment reaches its destination.

The point is that Lightning payment apps arent just flashy user interfaces to manage wallets or account balances they have to route payments through a fluctuating network graph. And ensuring a decent routing-success rate entails a number of subsidiary tasks. These include, for example, channel management opening and closing channels with other nodes in the network and liquidity management ensuring enough outbound and inbound liquidity.

Some users prefer managing their liquidity and available routes manually on self-hosted nodes. Most users, though, delegate these technical tasks to Lightning service providers, like Breez and Phoenix.

Reading this, did anyone think Well, thats simple! Theyre just describing a wallet!? Thats the point. There is no such thing as a Lightning wallet.

Give this network graph to a toddler with a box of crayons and try to find your way from minute to minute. Thats routing on the Lightning network. (Image: Annie Mole)

Metaphors are great when they help people to communicate a complex reality vividly and succinctly. When E.M. Forster writes that Life is a public performance on the violin in which you must learn the instrument as you go along, it hits. It doesnt require explanation; its already an explanation of something much bigger. Lightning wallet is not like that. As a metaphor, it confuses, misleads and obfuscates.

A better approach would probably be to use terms that describe functions (think: bolt cutter). If an app sends and receives payments, let's call it a payment app. If it's used to play podcasts and stream sats to podcasters, call it a podcast app. If it's used to manage finances, call it a finance app. This applies equally to bitcoin and fiat (remember PayPal, Venmo, CashApp etc.). The apps name should derive from its function, not how it implements that function. And if we must use metaphors, those metaphors should at least reflect the current state of our technological reality.

Were sure that many people will continue to refer to Lightning payment apps and custodial accounts as wallets, and that legislating language never works (or we would be writing these posts in Esperanto, rajto?). Im all for free speech, but simply using a term does not make it accurate or valid. Its still important to think about the relation between how we talk about Lightning and how we think about Lightning, and how the former might influence the latter for better or worse.

Our world is made of concepts (ask Immanuel Kant), and concepts are made of language (ask Ludwig Wittgenstein). Therefore, getting the language right should help us understand and shape the world. How do you expect to launch the Lightning revolution with a mere wallet?

This is a guest post by Roy Sheinfeld. Opinions expressed are entirely their own and do not necessarily reflect those of BTC Inc. or Bitcoin Magazine.

Read the original:
There Is No Such Thing As A Lightning Wallet - Bitcoin Magazine

Posted in Transhumanist | Comments Off on There Is No Such Thing As A Lightning Wallet – Bitcoin Magazine

Dean Kamen on the power of celebrating your own obsoletion – TechCrunch

Posted: July 27, 2022 at 2:59 am

More than 40 years and 1,000 or so patents after selling his first company, AutoSyringe, to healthcare giant Baxter, Dean Kamen still gets a charge describing breakthrough innovation. Its been five years since his organ fabricating project ARMI (Advanced Regenerative Manufacturing Institute) divided critics.

The project made more waves early last month, at the CNN-hosted conference Life Itself. Kamen paints the picture appearing on a panel at TC Sessions: Robotics today:

Doris Taylor, who moved up here from where she spent more than a decade in Texas, at the Texas Heart Institute, she gets on stage with a beaker. In the beaker is a miniature, pediatric-scale beating heart that was manufactured with induced pluripotent stem cells were put into a scaffold of preexisting organ. Within an hour of that presentation, Martine Rothblatt, the founder and chairman of United Therapeutics, is on stage and they roll out from backstage an almost surrealistic, lit from the top of the box. A panel opens, and what emerges out of the top of this platform is a scaffold of a human lung, that was printed, entirely printed at the smallest scale any printer has ever operated.

Inventor Dean Kamen looks on as over 110,000 pounds of personal protective equipment (PPE), shipped from Shanghai, China, is unloaded from a cargo plane at Manchester-Boston Regional Airport in Manchester, New Hampshire, Thursday, April 30, 2020. The equipment will be used for medical workers and first responders in their fight against the virus outbreak. (AP Photo/Charles Krupa)

Kamen is first to admit, however, that the path to all success is paved with failure. The trick is learning the right lesson.

What Ive learned from failure is go back and decide was the fundamental goal wrong thats why it failed, you succeeded, but nobody needs this or did the available technology and your systems integration and application have it wrong, in which case, youve now learned enough, go try again, go use a different approach, Kamen explains. Pick yourself up, try again, using a different approach. And it really doesnt matter how many times you fall down. If you fall down five times, but you stand up six, its okay. And in the end, you only need a win every once in a while to keep your confidence up. And hopefully, to give you the resources to keep going even though inevitably youll have failures, let the projects fail, dont let the people fail.

These are among the fundamentals Kamen has attempted to infuse into FIRST, the education program he co-founded in 1989, with MIT professor Woodie Flowers. It is best known for its robotics competitions, which center around competitive builds of robots and other projects, bringing the teamwork and enthusiasm of sports to STEM education subjects that might otherwise turn off students who traditionally encounter them in more formal and staid settings.

Kids wont go to class, or theyll take math for 45 minutes between phonics and spelling, one day a week. But theyll go after school for three hourse, every single day to get better at football or get better at basketball. So I said, look, were not competing for the hearts and minds of kids with the science fair and the spelling bee, were competing with the things that they invest all of their time, energy and passion in. So lets use that model make it aspirational, make it after school. Dont give them quizzes and tests, give them letters and trophies. Bring the school band and the mascots.

U.S. Sen. Jeanne Shaheen (D-NH), right, looks toward inventor Dean Kamen as over 110,000 pounds of personal protective equipment (PPE) from Shanghai, China, delivered to protect medical workers and first responders fighting the COVID-19 virus outbreak, is unloaded from a cargo plane at Manchester-Boston Regional Airport in Manchester, New Hampshire, Thursday, April 30, 2020. (AP Photo/Charles Krupa)

Perhaps the hardest-fought lesson of all, however, is understanding, accepting and even welcoming the fact that progress in technology and sciences means that one day your best work will be eclipsed.

You have to be more than prepared for it. You have to be confident it will happen, and you have to celebrate it. I celebrate it more when its me that obsoleted the last thing I did, but if somebody else can obsolete it and if I get to a point where I need a better clinical solution than a dialysis machine or an insulin pump, if I can get to a place with somebody elses technology to gave me a new organ or a prosthetic limb or something, I need to have a better quality of life, I will thank that person. And I hope I will return that favor by giving them something of value that we invented.

Excerpt from:
Dean Kamen on the power of celebrating your own obsoletion - TechCrunch

Posted in Texas Stem Cells | Comments Off on Dean Kamen on the power of celebrating your own obsoletion – TechCrunch

Westin and Sehn Carve Out the Role of CAR T-Cell Therapy and Transplant in Primary Refractory DLBCL – OncLive

Posted: July 27, 2022 at 2:59 am

CAR T-cell therapy, autologous stem cell transplant (ASCT), and novel agents each have a role to play in the second-line management of patients with primary refractory diffuse large B-cell lymphoma (DLBCL), according to Jason Westin, MD, MS, FACP, and Laurie H. Sehn, MD, MPH, who provided perspective on the optimal use of each modality during a case-based presentation at the 2022 Pan Pacific Lymphoma Conference.1,2

Westin, director, Lymphoma Clinical Research, section chief, Aggressive Lymphoma, and associate professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center, started the session by presenting a case of a 70-year-old man with a failure to thrive with progressive bowel obstruction. The man had decreased urine output, a performance status of 1, rising lactate dehydrogenase (LDH) of 1.5 x the upper limit of normal, and an International Prognostic Index (IPI) of 4. A biopsy confirmed high-grade double-hit DLBCL with MYC and BCL2 translocations.

The patient was started with dose-adjusted R-EPOCH and although his gastrointestinal (GI) symptoms improved during the first cycle of chemotherapy, he developed worsening shoulder pain in weeks 2 and 3 of cycle 2 of treatment. An interim PET scan performed after 2 cycles of treatment confirmed a significant improvement in tumor burden but persistent hypermetabolic lesion in the right humerus and a standardized uptake value of 7.

There is a lot of controversy in our field about how we interpret an interim positive PET [result], Westin said. We know the negative predictive value is strong, but the positive predictive value is rather poor.

As such, a bone biopsy was performed on the lesion in the humerus, confirming CD10-positive B-cell lymphoma. Westin argued that the patient was unlikely to achieve a complete response (CR) at the end of treatment, and as such, alternative regimens should then be considered. However, patients with refractory disease have poor outcomes with salvage chemotherapy, which led Westin to consider a clinical trial.

[ZUMA-12 (NCT03761056)] was the clinical trial we had open at the time, which Ill argue is something we should consider for our patients who have high-risk disease in the frontline setting: an early switch to a CAR T-cell therapy, Westin said.

The phase 2 trial enrolled patients with high-grade double-hit or triple-hit B-cell lymphoma and large B-cell lymphoma with an IPI score of at least 3.3 Patients had to have a positive interim PET scan following 2 cycles of an anti-CD20 monoclonal antibody and anthracycline-containing regimen.

Patients underwent leukapheresis and optional nonchemotherapy bridging therapy followed by conditioning chemotherapy consisting of 30 mg/m2 of intravenous (IV) fludarabine and 500 mg/m2 of IV cyclophosphamide on days 5, 4, and 3. They subsequently received a single IV infusion of axicabtagene ciloleucel (axi-cel; Yescarta) at 2 x 106 CAR T cells/kg on day 0.

The CR rate achieved with the CAR T-cell therapy was impressive, according to Westin, at 78% (n = 29) and benefit was consistent across subgroups. The 1-year event-free survival rate with axi-cel was 72.5% (95% CI, 53.1%-84.9%).

In terms of safety, cytokine release syndrome (CRS) occurred in all patients, but the rate of grade 3 CRS was low, at 8%, Westin said.

Westin acknowledged that although axi-cel could be saved for relapse, findings presented at the 2021 ASH Annual Meeting and Exposition comparing the populations in ZUMA-12 and ZUMA-1 (NCT02348216) showed better CAR T-cell expansion in patients who had received less chemotherapy.4

With this in mind, the patient was enrolled to ZUMA-12. He developed late, low-grade CRS and immune effector cellassociated neurotoxicity syndrome (ICANS) but went on to achieve a CR with treatment.

Hes more than 2 years out now without any relapse or any late toxicities, Westin said. Should you switch all patients with a positive interim PET? No. However, if you have circulating tumor DNA or a positive biopsy, its reasonable to consider switching to a different therapy. Having a non-chemotherapy option for chemorefractory disease makes treatment switch more attractive.

Laurie H. Sehn, MD, MPH, a clinical associate professor in the division of medical oncology at the University of British Columbia and the British Columbia Cancer Agency, subsequently presented a case of a 66-year-old man with stage IVB DLBCL with lymphadenopathy above and below the diaphragm. He had a large bowel mass that was biopsied, confirming germinal center B-cell DLBCL and was negative for MYC, BCL2, and BCL6 on fluorescence in situ hybridization.

The patient was treated with 6 cycles of R-CHOP and achieved a CR; however, 6 months later, the patient developed GI bleeding and was found to have recurrent DLBCL of the GI tract. He was started on 2 cycles of R-GDP and achieved a CR, with the intention of heading to ASCT.

Our longstanding management for relapsed/refractory DLBCL has been to take patients down the ASCT route, Sehn stated. However, only approximately half of patients will respond to salvage chemotherapy and proceed to transplant, making the decision on what to pursue a difficult one, Sehn explained.

The 3 randomized trials that have evaluated second-line CAR T-cell therapyZUMA-7 (NCT03391466), TRANSFORM (NCT03575351), and BELINDA (NCT03570892)have yet to show an overall survival (OS) benefit, supporting the rationale to opt for a stepwise approach.

Sehn noted that although all 3 trials demonstrated that CAR T-cell therapy would be the preferred approach in the second-line setting in the intent-to-treat population, they do not provide insight into the preferred approach for patients who respond to salvage chemotherapy.

This is a scenario we all face because most people do receive bridging therapy prior to going on to CAR T-cell therapy, even if your intention is to give it in the second-line setting, Sehn said. As such, we all face this question.

Although not randomized data, Sehn highlighted findings from a Center for International Blood and Marrow Transplant Research retrospective registry analysis which showed that patients in partial remission after salvage chemotherapy had a lower rate of relapse and disease progression (P = .010), as well as improved OS (P = .007).5

Moreover, supplementary findings from the ZUMA-7 trial demonstrated a comparable duration of response among responders, regardless of whether they were randomized to axi-cel or standard of care (HR, 0.763; 95% CI, 0.488-1.108).6

Additionally, Sehn stated that the one-size-fits-all design of the CAR T-cell therapy trials is not likely to hold up in the real world because not everyone will benefit from cellular therapy. Sehn cited data published in Blood Advances showing that predictive factors, including at least 2 extranodal sites, total metabolic tumor volume greater than 80 mL, and elevated LDH, is associated with poor outcomes following CAR T-cell therapy.7

In the CAR T trials, everybody went to CAR T based on an intent-to-treat approach, and even though those arms did better, most patients did relapse or progress subsequently, Sehn said. Just blindly taking everyone on to CAR T is probably not going to be feasible in most clinical settings.

In addition, the short- and long-term toxicities associated with CAR T-cell therapy are worth considering, said Sehn, who highlighted CRS, ICANS, prolonged cytopenias, hypogammaglobulinemia, CD19 loss, and B-cell aplasia in particular, which was present in 34% of patients on the ZUMA-7 trial up to 18 months after infusion.5

For patients who are not candidates to receive CAR T-cell therapy or ASCT, Sehn highlighted the potential of novel agents such as polatuzumab vedotin-piiq (Polivy) plus bendamustine and rituximab (Rituxan) and the combination of tafasitamab-cxix (Monjuvi) and lenalidomide (Revlimid), which have shown responses of 40.2% and 60%, and a median progression-free survival of 5.1 months and 11.6 months, respectively.7,8

For patients with primary refractory or early relapsing DLBCL, the data do argue for CAR T-cell therapy as the preferred potential second-line therapy. However, theres still a role for ASCT; [this approach] still might be suitable for patients who respond to salvage or bridging therapy, Sehn concluded. One of the main things we need to figure out is who shouldnt go to CAR T-cell therapy, as its unlikely to work for patients with fully uncontrollable disease. As far as the novel agents go, there are encouraging data to suggest that these [drugs] will improve outcomes in the refractory setting, although we do need predictive markers to figure out which option to select for which patient.

See the original post:
Westin and Sehn Carve Out the Role of CAR T-Cell Therapy and Transplant in Primary Refractory DLBCL - OncLive

Posted in Texas Stem Cells | Comments Off on Westin and Sehn Carve Out the Role of CAR T-Cell Therapy and Transplant in Primary Refractory DLBCL – OncLive

Unanticipated findings cast new light on the genetic regulation of different brain tumors – Baylor College of Medicine

Posted: July 27, 2022 at 2:59 am

Cancer cells express different genes than normal cells, and these new gene expression patterns are key to cancer behavior. One way cells can alter gene expression is by adding small chemical modifications to the DNA or associated proteins called epigenetic markers that determine which genes are turned on or off.

Take brain tumors, for example. A team led by researchers at Baylor College of Medicine has investigated the genetic regulation of brain tumor behavior. Specifically, they studied Sox9-mediated mechanisms of epigenetic dysregulation in two mouse models of human brain tumors: high-grade glioma (HGG) and ependymoma (EPN).

Sox9, a well-known transcription factor, has emerged as a key regulator of epigenetic modifications and gene expression programs that contribute to brain tumor growth; however, how Sox9 achieves this is not well known, said co-first author Dr. Debosmita Sardar, postdoctoral associate in the lab of Dr. Benjamin Deneen at Baylor.

We knew that Sox9 is elevated in both HGG and EPN. Also, we knew that these tumors have different epigenetic profiles, said co-first author Hsiao-Chi-Eileen-Chen, graduate student in the Deneen lab. We wanted to know whether Sox9 was involved in shaping these distinct profiles and the mechanism that led to them.

We expected that Sox9s contribution to set up the tumors epigenetic patterns would be the same, said Deneen, professor and Dr. Russell J. and Marian K. Blattner Chair of neurosurgery and the Center for Cancer Neuroscience at Baylor. Deneen also is the corresponding author of the work.

The function of a gene, in this case Sox9, is assumed to be the same regardless of the cell type in which the gene is expressed. We found something unexpected in that Sox9 function was dramatically different in these two different tumors.

The researchers manipulated Sox9 expression in the mouse models and found that increasing Sox9 suppressed tumor growth in HGG but promoted it in EPN. Surprisingly, Sox9 regulated the epigenetic patterns of HGG and EPN in different ways. In HGG, Sox9 mediated its effect by interacting with a group of proteins called histone deacetylation complex, while in EPN Sox9 interacted with oncofusion proteins. Sox9 has different protein-protein interactions in different tumors.

This is what is really driving the different ways Sox9 regulates epigenetic patterns in these tumors, Sardar said. Its actions are tumor-specific and we essentially took advantage of state-of-the art proteomic technologies to uncover these distinct mechanisms.

Importantly, we also see these distinct Sox9 protein-protein interactions in human HGG tumor samples graciously provided by Dr. Ganesh Rao, Marc J. Shapiro professor and chair of neurosurgery at Baylor, Chen said. Also, our collaboration with Dr. Stephen Mack at St. Jude Childrens Research Hospital was crucial for comparing epigenetic datasets of our mouse models with clinical tumor samples from human patients.

This revealed a strong overlap between epigenetic profiles in our mouse models and human tumors, establishing these mouse models as powerful tools to understand clinically relevant tumor behaviors. These findings suggest new possibilities for developing novel therapies directed at epigenetic mechanisms.

Looking to read all the details of this work? Find it in Proceedings of the National Academy of Sciences.

Other contributors to this work include Amanda Reyes, Srinidhi Varadharajan, Antrix Jain, Carrie Mohila, Rachel Curry, Brittney Lozzi, Kavitha Rajendran, Alexis Cervantes, Kwanha Yu, Ali Jalali and Ganesh Rao. The authors are affiliated with one or more of the following institutions: Baylor College of Medicine, Center for Stem Cells and Regenerative Medicine at Baylor, Center for Cancer Neuroscience at Baylor, St. Jude Childrens Research Hospital, University of Houston and Texas Childrens Hospital.

Financial support for this project was provided by grants from the National Institutes of Health (R01-NS071153 to BD, R01-NS124093, R01NS094615, K08-NS110976, 1R01NS116361, 1K99-DC019668, P30 CA125123, S10OD026804), National Cancer Institute-Cancer Therapeutic Discovery (U01-CA217842) and the Diana Helis Henry and Adrienne Helis Malvin Medical Research Foundation. Further support was provided by an ALSF A Award, a CPRIT Scholar in Cancer Research Award, CPRIT Core Facility Award (RP210227), Pediatric Brain Tumor Foundation, V Scholar Foundation and ALSAC St Jude Childrens Research Hospital.

By Ana Mara Rodrguez, Ph.D.

Originally posted here:
Unanticipated findings cast new light on the genetic regulation of different brain tumors - Baylor College of Medicine

Posted in Texas Stem Cells | Comments Off on Unanticipated findings cast new light on the genetic regulation of different brain tumors – Baylor College of Medicine

Artificial Intelligence in Personalized Medicine, Genomic Sequencing Advances, Human Brain Organogenesis, Building Trust with Patients, Guiding…

Posted: July 27, 2022 at 2:57 am

CHICAGO, July 24, 2022 /PRNewswire/ -- At the 2022 AACC Annual Scientific Meeting & Clinical Lab Expo, laboratory medicine experts will present the cutting-edge research and technology that is revolutionizing clinical testing and patient care. From July 24-28 in Chicago, the meeting's 250-plus sessions will deliver insights on a broad range of timely healthcare topics. Highlights include discussions exploring the use of artificial intelligence (AI) in personalized medicine, advances in multiplexed genomic sequencing and imaging, real-life applications of human brain organogenesis, how to build trust with patients, and guiding clinical decisions with mass spectrometry.

(PRNewsfoto/AACC)

AI in Personalized Medicine. Precision medicine involves tailoring treatments to individual patients and, increasingly, clinicians are using AI in their clinical prediction models to do this. In the meeting's opening keynote, Dr. Lucila Ohno-Machado, health associate dean of informatics and technology at the University of California San Diego, will introduce how AI models are developed, tested, and validated as well as performance measures that may help clinicians select these models for routine use.

Multiplexed Genomic Sequencing and Imaging. Thanks to advances in multiplexed genomic sequencing and imaging, we can identify small but crucial differences in DNA, RNA, proteins, and more. These techniques have also undergone a 50-million-fold reduction in cost and comparable improvements in quality since they first emerged. In spite of this, healthcare is just beginning to catch up with the implications of these technologies. Dr. George Church, AACC's 2022 Wallace H. Coulter Lectureship Awardee and founding core faculty and lead at the Synthetic Biology Wyss Institute at Harvard University, will discuss advances and implications of multiplex technologies at this plenary session.

Applications of Human Brain Organoid Technology. The human brain is a very complex biological system and is susceptible to several neurological and neurodegenerative disorders that affect millions of people worldwide. In this plenary session, Dr. Alysson R. Muotri, professor of cellular and molecular medicine at the University of California San Diego School of Medicine, will explore the concept of human brain organogenesis, or how to recreate the human brain in a dish. Several applications of this technology in neurological care will be discussed.

Story continues

Building Trust in Healthcare. The world is having a trust crisis that is affecting healthcare delivery across the globe. Dr. Thomas Lee, chief medical officer of Press Ganey Associates and professor of health policy and management at the Harvard T.H. Chan School of Public Health, will describe the importance of building trust among patients and healthcare workers in this plenary session. He will explore a three-component model for building trust, and the types of interventions most likely to be effective.

Guiding Clinical Decisions with Mass Spectrometry. In this, the meeting's closing keynote, Dr. Livia Schiavinato Eberlin, associate professor of surgery and director of translational and innovations research at Baylor College of Medicine, will discuss the development and application of direct mass spectrometry techniques used in clinical microbiology labs, clinical pathology labs, and the operating room. The presentation will focus on results obtained in ongoing clinical studies employing two direct mass spectrometry techniques, desorption electrospray ionization mass spectrometry imaging and the MasSpec Pen technology.

Additionally, at the Clinical Lab Expo, more than 750 exhibitors will display innovative technologies that are just coming to market in every clinical lab discipline.

"Laboratory medicine's capacity to adapt to changing healthcare circumstances and use the field's scientific insights to improve quality of life is unparalleled. This capacity is constantly growing, with cutting-edge diagnostic technologies emerging every day in areas as diverse as mass spectrometry, artificial intelligence, genomic sequencing, and neurology," said AACC CEO Mark J. Golden. "The 2022 AACC Annual Scientific Meeting will shine a light on the pioneers in laboratory medicine who are mobilizing these new advances to enhance patient care."

Session Information

AACC Annual Scientific Meeting registration is free for members of the media. Reporters can register online here: https://www.xpressreg.net/register/aacc0722/media/landing.asp

AI in Personalized Medicine

Session 11001 Biomedical Informatics Strategies to Enhance Individualized Predictive ModelsSunday, July 245-6:30 p.m.U.S. Central Time

Multiplexed Genomic Sequencing and Imaging

Session 12001 Multiplexed and Exponentially Improving TechnologiesMonday, July 258:45 10:15 a.m.U.S. Central Time

Applications of Human Brain Organoid Technology

Session 13001 Applications of Human Brain Organoid TechnologyTuesday, July 268:45 10:15 a.m.U.S. Central Time

Building Trust in Healthcare

Session 14001 Building Trust in a Time of TurmoilWednesday, July 278:45 10:15 a.m.U.S. Central Time

Guiding Clinical Decisions with Mass Spectrometry

Session 15001 Guiding Clinical Decisions with Molecular Information provided by Direct Mass Spectrometry TechnologiesThursday, July 288:45 10:15 a.m.U.S. Central Time

All sessions will take place in Room S100 of the McCormick Place Convention Center in Chicago.

About the 2022 AACC Annual Scientific Meeting & Clinical Lab ExpoThe AACC Annual Scientific Meeting offers 5 days packed with opportunities to learn about exciting science from July 24-28. Plenary sessions will explore artificial intelligence-based clinical prediction models, advances in multiplex technologies, human brain organogenesis, building trust between the public and healthcare experts, and direct mass spectrometry techniques.

At the AACC Clinical Lab Expo, more than 750 exhibitors will fill the show floor of the McCormick Place Convention Center in Chicago with displays of the latest diagnostic technology, including but not limited to COVID-19 testing, artificial intelligence, mobile health, molecular diagnostics, mass spectrometry, point-of-care, and automation.

About AACCDedicated to achieving better health through laboratory medicine, AACC brings together more than 70,000 clinical laboratory professionals, physicians, research scientists, and business leaders from around the world focused on clinical chemistry, molecular diagnostics, mass spectrometry, translational medicine, lab management, and other areas of progressing laboratory science. Since 1948, AACC has worked to advance the common interests of the field, providing programs that advance scientific collaboration, knowledge, expertise, and innovation. For more information, visit http://www.aacc.org.

Christine DeLongAACCSenior Manager, Communications & PR(p) 202.835.8722cdelong@aacc.org

Molly PolenAACCSenior Director, Communications & PR(p) 202.420.7612(c) 703.598.0472mpolen@aacc.org

Cision

View original content to download multimedia:https://www.prnewswire.com/news-releases/artificial-intelligence-in-personalized-medicine-genomic-sequencing-advances-human-brain-organogenesis-building-trust-with-patients-guiding-patient-decisions-with-mass-spectrometry-and-much-more-to-be-explored-at-the-2022-aac-301592069.html

SOURCE AACC

Read more here:
Artificial Intelligence in Personalized Medicine, Genomic Sequencing Advances, Human Brain Organogenesis, Building Trust with Patients, Guiding...

Posted in Molecular Medicine | Comments Off on Artificial Intelligence in Personalized Medicine, Genomic Sequencing Advances, Human Brain Organogenesis, Building Trust with Patients, Guiding…

Faculty Positions in Life Science and Medicine at National Tsing Hua University (Taiwan) job with National Tsing Hua University | 37287332 – The…

Posted: July 27, 2022 at 2:57 am

Faculty Positions in Life Science and Medicine at

National Tsing Hua University (Taiwan)

Location

Hsinchu, Taiwan

DeadlinePlease check the following link for information.

Position description and other specified information

Required Qualifications:PhD in related fields.

Application:All applicants are required to submit aCurriculum Vitae and othersupporting materials.

About NTHU (Please find more in company)

At National Tsing Hua University (NTHU), we believe that everyone deserves the opportunity to explore and realize their unique potential. In everything we do, NTHU will continue to uphold our core values of inclusivity, equality, and inclusivity in safeguarding academic freedom and shared governance.NTHU is widely recognized as a foremost incubator of future leaders in industry and academia. NTHUs consistent record of excellence is exemplified by the outstanding achievement of our faculty and alumni, among whom are two Nobel laureates in physics, one Nobel laureate in chemistry, and one Wolf Prize winner in mathematics.

Salary

1.Statutory Salary:

The statutory salary for a full-time facultymember includes Base SalaryandAdditional Academic Research Pay.

(Please refer to https://yushan.site.nthu.edu.tw/p/412-1518-17613.php?Lang=en)

2. Non-statutory (Additional) Salary:

(1) Yushan Fellows and Yushan Young Fellows: If approved by the Ministry of Education as a Yushan Scholar or Yushan Young Scholar, theMOE willprovide the subsidyfor the non-statutory (additional) salary:

(Please refer tohttps://yushan.moe.gov.tw/TopTalent/EN/Intro)

(2) Flexible Salary Reward: If not approved by the MOE Yushan Fellow Program, NTHU may provide a Flexible Salary Reward if it conforms to the regulations of the NTHU Newly-Recruited Faculties Flexible Salary Reward.

(Please refer to https://yushan.site.nthu.edu.tw/p/412-1518-18110.php?Lang=en)

(3) Newly appointed foreigner (non-Taiwanese) faculty members are eligible to apply for an extra compensation of 25,000 NTD/month till 2027.

Taiwan is ranked 19th in global purchasing power parity (PPP) indicating high standard of living with stable and low cost of living.

(Please refer to https://en.wikipedia.org/wiki/List_of_countries_by_GDP_(PPP)#cite_note-:0-1)

We also provide

1. Subsidy for NTHU Newly-Recruited Faculty Academic Research (start-up subsidy)

2. Subsidy for Guest House and Accommodation

3. Education of children

About College of Life Science(https://cls.site.nthu.edu.tw/app/index.php?Lang=en)

Established in 1991 as the very first Department of Life Science in Taiwan, the Department of Life Science allows students to explore various areas of life science in an integrated yet diverse program built upon a solid foundation of chemistry, physics, mathematics and biology. In 2022, the College of Life Science was reorganized and is now comprised of the Department of Life Science, the Department of Medical Science, the Interdisciplinary Program of Life Science, the School of Medicine and five Institutes, the Institute of Molecular and Cell Biology, the Institute of Bioinformatics and Structural Biology, the Institute of Molecular Medicine, the Institute of Biotechnology, and Institute of Systems Neuroscience. The Department of Life Science, Medical Science and Interdisciplinary Program offer undergraduateBachelor of Science(B.Sc.) programs in Biology and Medical Science whereas the five Institutes offer graduate programs in a variety of research areas. The School of Medicine offers Doctor of Medicine.

Five educational goals of the College of Life Science (ERIGS):

1. Education: Excellence in education and learning in the fields of life science

2. Research: Innovative research and research training at the highest international level in the fields of life science

3. Internal Mobilization: Supporting the development of students and colleagues

4. Globalization: Widening global worldview and providing international environment for the studies of life science

5. Social Responsibility: Model for sharing common wealth from life science research

We strive to train our young life scientists as prophetic leaders of future generations with a passion for science, and compassion for life and a desire to transform the world.

Chronology

1973 Institute of Molecular Biology (IMB) established

1974 Masters program for IMB established

1984 Ph.D. program for IMB established

1985 Re-organized as Institute of Life Science

1987 Life Science Building I completed

1991 Institute of Biomedicine and Department of Life Science established

1992 College of Life Science established

1995 All institutes merged into Department of Life Science

1997 Institute of Biotechnology established

1998 Institute of Radiation Biology merged with the College

2002 Reorganized into four institutes and Department of Life Science

2004 Brain Research Center established

2008 Interdisciplinary Program of Life Science and Institute of Systems Neuroscience established

2010 Department of Medical Science established

2013 Interdisciplinary Neuroscience Ph.D. Degree Program established

2016 Ph.D. Program in Bioindustrial Technology established

2022 School of Medicine established

2022 Reorganized into five institutes, three departments and one interdisciplinary program

See original here:
Faculty Positions in Life Science and Medicine at National Tsing Hua University (Taiwan) job with National Tsing Hua University | 37287332 - The...

Posted in Molecular Medicine | Comments Off on Faculty Positions in Life Science and Medicine at National Tsing Hua University (Taiwan) job with National Tsing Hua University | 37287332 – The…

Page 311«..1020..310311312313..320330..»